Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
AHK-Cu Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
AHK-Cu at a glance
What it is
AHK-Cu, a synthetic Ala-His-Lys tripeptide complexed with copper (copper tripeptide-3), a copper-carrier signaling peptide
Researched for
Reported in research for hair-follicle (dermal papilla) support and skin/tissue regeneration; primarily in vitro and ex vivo work
Commonly reported range
Topical: 2-5% scalp serum; subcutaneous (community-reported): ~50-200 mcg daily
Route reported
Topical scalp serum most common; subcutaneous injection also community-reported
Reported frequency
Once (sometimes twice) daily
Reported cycle
Community-reported use of 8-12 weeks or longer, with results discussed over 3-6 months
Plasma half-life
Not formally established in humans; small copper-peptide complexes are believed to clear rapidly
Regulatory status
Not FDA-approved; sold for research use only; used cosmetically as copper tripeptide-3; not specifically listed by WADA
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
AHK-Cu is a synthetic tripeptide (alanine-histidine-lysine) that chelates a copper ion, allowing it to act as a copper carrier and signaling molecule. In research models it is reported to target dermal papilla cells at the base of the hair follicle, where copper delivery is associated with increased cell proliferation. Proposed mechanisms reported in the literature include stimulation of vascular endothelial growth factor (VEGF), a shift in apoptosis-related proteins (increased Bcl-2, decreased Bax) that may extend the follicle's growth (anagen) phase, and modulation of extracellular-matrix and growth-factor activity relevant to tissue repair. A notable research finding is a biphasic dose response: follicle growth was stimulated at very low concentrations but inhibited at higher ones, suggesting an optimal concentration window. These are proposed mechanisms from laboratory and tissue models, not confirmed clinical outcomes.
Researched effects
Reported and studied effects, described as research findings and community observations rather than guaranteed outcomes, include increased dermal papilla cell proliferation in vitro, extension of the follicle growth phase in tissue models, and support for the appearance of thicker or fuller hair in community anecdote. In skin-focused research it is discussed alongside other copper peptides for wound-healing and collagen/extracellular-matrix support. Human efficacy data demonstrating actual hair regrowth is limited; most evidence comes from cell cultures and ex vivo follicle models. These are research findings, not guaranteed outcomes, and individual results are not established.
Evidence & regulatory status
Evidence base: Most support comes from in vitro and ex vivo studies (notably a 2007 hair-follicle organ-culture study) showing dermal papilla proliferation and anagen-phase effects; large, long-term human clinical trials are absent.
Regulatory: AHK-Cu is not FDA-approved for any therapeutic indication; it is marketed for research use only, and as 'copper tripeptide-3' it appears as a cosmetic ingredient rather than an approved drug.
Research use: Product sold for laboratory/research purposes is labeled not for human consumption; the information here is educational and describes what is reported, not a recommendation to use it.
Dosage — reported ranges (overview)
The following are examples of what is reported in research protocols and community discussion, not a recommendation or a personal dose. For topical use, sources describe scalp serums in roughly the 2-5% concentration range applied once or twice daily, with some clinical research protocols using much lower solutions (around 0.03%, or ~300 mcg/mL). For subcutaneous use, community sources report approximately 50-200 mcg once daily. Because copper peptides show a biphasic (optimal-window) dose response in research, higher is not necessarily better. There is no official or FDA-established dosing for AHK-Cu, and human safety and efficacy dosing have not been formally determined.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
AHK-Cu is most often used topically, but lyophilized (freeze-dried) research vials can also be reconstituted with bacteriostatic water for the subcutaneous route some community sources describe. For microgram (mcg) dosing, the concentration in mcg/mL equals the vial's total mcg divided by the water added: concentration = (vial mg x 1000) / water mL. On a U-100 insulin syringe, 100 units = 1 mL, so the units to draw for a given dose = dose (mcg) / concentration (mcg/mL) x 100. Worked example: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives (10 x 1000) / 2 = 5,000 mcg/mL; a 100 mcg example dose would be 100 / 5,000 x 100 = 2 units on a U-100 syringe. This is concentration math only, not a personal dose. For topical serums, concentration is instead expressed as % w/v (for example, 2% = 20 mg/mL).
Bac water added
Concentration
50 mcg (low example)
200 mcg (high example)
1 mL
10,000 mcg/mL
0.5 units
2 units
2 mL
5,000 mcg/mL
1 unit
4 units
3 mL
3,333 mcg/mL
1.5 units
6 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
For topical use, community sources describe applying the serum to clean, dry scalp or skin and leaving it in, similar to how other leave-on scalp treatments are applied. For the subcutaneous route some sources report, small insulin syringes are used and injection sites are typically rotated; standard aseptic handling (clean hands, alcohol-swabbed vial stopper and site) is described in general peptide-handling references. None of this is medical guidance, and AHK-Cu is not approved for human injection; this section describes reported general practice only.
Half-life & frequency rationale
A formal plasma half-life for AHK-Cu has not been established in published human pharmacokinetic studies. Small copper-peptide complexes of this type are generally believed to be cleared or metabolized rapidly (on the order of hours), which is one reason topical and daily dosing schedules are commonly reported. Treat any half-life figure as approximate and not clinically validated.
Side effects, safety & contraindications
Human safety data is limited. Reported effects are generally mild and include local skin irritation, redness, or itching at the application or injection site, and rare allergic reactions. The main theoretical concern is cumulative copper exposure: combining AHK-Cu with other copper sources (including other copper peptides or copper supplements) could raise total copper load, which in excess is associated with nausea, vomiting, and other systemic effects. It is described as contraindicated for people with Wilson's disease or other copper-metabolism disorders. Because robust long-term human data does not exist, the full side-effect profile is not well characterized.
Stacking — overview
In community and research discussion, AHK-Cu is most often paired with other regenerative peptides rather than used alone, particularly its better-studied copper-peptide sibling GHK-Cu for hair and skin research contexts. Because both are copper-carrying peptides, discussions frequently flag the importance of not stacking multiple high-dose copper sources at once due to cumulative copper exposure. The pairings below are examples reported in the community, not recommendations, and none have established clinical safety data as combinations.
Hair & skin regenerative stack
AHK-Cu + GHK-Cu (copper-peptide pairing for hair/skin research)
Tissue-repair pairing
AHK-Cu + BPC-157 or TB-500
Storage & handling
Lyophilized (freeze-dried) powder: reported as stable refrigerated; longer-term storage at -20C (about 1 year) or -80C (up to ~2 years), kept away from heat, light, and moisture.
Reconstituted or in-solution serum: store refrigerated at 2-8C, protect from light, and use within roughly 28-30 days; do not refreeze.
References
Information is compiled from published in vitro and ex vivo copper-peptide research (including a 2007 hair-follicle organ-culture study), cosmetic-ingredient references for copper tripeptide-3, and community/research-supplier summaries; it is educational only and not a substitute for professional or medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is AHK-Cu?
AHK-Cu is a synthetic tripeptide made of alanine, histidine, and lysine bound to a copper ion (also called copper tripeptide-3). It is studied as a copper-carrier signaling peptide, mainly in hair-follicle and skin-regeneration research. It is not an FDA-approved drug.
Is AHK-Cu used topically or injected?
The most commonly reported route is topical, as a 2-5% scalp serum. Some community sources also report subcutaneous injection at roughly 50-200 mcg daily, but there is no approved or clinically established injection protocol.
How is AHK-Cu different from GHK-Cu?
Both are copper-binding peptides used in skin and hair research. GHK-Cu (glycine-histidine-lysine copper) is the more extensively studied of the two, while AHK-Cu (alanine-histidine-lysine copper) is newer and reported to be more specifically oriented toward dermal papilla cells in hair-follicle models. Evidence for both in humans is limited.
Does AHK-Cu actually regrow hair?
Research in cell cultures and ex vivo follicle models reports effects on dermal papilla proliferation and the growth phase, but large human trials demonstrating actual regrowth are absent. Any hair benefit is a research finding and community anecdote, not a proven or guaranteed outcome.
Is AHK-Cu banned in sports?
AHK-Cu is not specifically named on the WADA Prohibited List. However, athletes should verify current status themselves, since copper peptides and growth-factor-modulating compounds can fall under broad prohibited categories, and formulations vary.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
